Harrow Shakes Up Imprimis Leadership Following Accusation from CA Board of Pharmacy

Published on Oct 09, 2025

Amid significant scrutiny of its drug compounding practices, ophthalmic pharmaceutical company Harrow (HROW) announced October 6 that John Saharek, the former CEO and president of its drug compounding arm, ImprimisRx, had stepped down. On the same day, Harrow said Frank Mullery would serve as the new CEO of ImprimisRx and Bridseida Cruz as Head of […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.